| [1] |
Zhu AX, Hezel AF. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities[J]. Hepatology, 2011, 53(2): 695-704.
|
| [2] |
Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities[J]. Nat Rev Drug Discov, 2014, 13(2): 140-156.
|
| [3] |
Cohen MM Jr. The AKT genes and their roles in various disorders[J]. Am J Med Genet A, 2013, 161A(12): 2931-2937.
|
| [4] |
Peng SF, Lee CY, Hour MJ, et al. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human osteosarcoma cells through the Akt-Bad signaling pathway[J]. Int J Oncol, 2014, 44(1): 238-246.
|
| [5] |
Jayasooriya RG, Dilshara MG, Choi YH, et al. Tianeptine sodium salt suppresses TNF-α-induced expression of matrix metalloproteinase-9 in human carcinoma cells via suppression of the PI3K/Akt-mediated NF-κB pathway[J]. Environ Toxicol Pharmacol, 2014, 38(2): 502-509.
|
| [6] |
Li Z, Yang Z, Lapidus RG, et al. IKK phosphorylation of NF-kB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer[J]. Am J Cancer Res, 2015, 5(10): 3098-3110.
|
| [7] |
Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms,modes of activation and therapeutic targeting[J]. Nat Rev Cancer, 2015, 15(1):7-24.
|
| [8] |
Kavitha JV, Rosario FJ, Nijland MJ, et al. Down-regulation of placental mTOR,insulin/IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon[J]. FASEB J, 2014, 28(3): 1294-1305.
|
| [9] |
Chen MH, Chiang KC, Cheng CT, et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma[J]. Oncotarget, 2014, 5(9): 2372-2389.
|
| [10] |
Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy[J]. Tumour Biol, 2013, 34(6): 3637-3648.
|
| [11] |
Huang Q, Liu Z, Xie F, et al. Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway[J]. ScientificWorldJournal, 2014: 179698.
|
| [12] |
Menakongka A, Suthiphongchai T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion[J]. World J Gastroenterol, 2010, 16(6): 713-722.
|
| [13] |
Liu R, Zhao R, Zhou X, et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2[J]. Hepatology, 2014, 60(3): 908-918.
|
| [14] |
Xu D, Ma Y, Zhao B, et al. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo[J]. Oncol Rep, 2014, 31(5): 2063-2070.
|
| [15] |
Xiong GP, Zhang JX, Gu SP, et al. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell[J]. Neoplasma, 2012, 59(4):409-415.
|
| [16] |
Utispan K, Sonongbua J, Thuwajit P, et al. Periostin activates integrin α5β1 through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma[J]. Int J Oncol, 2012, 41(3): 1110-1118.
|
| [17] |
Loilome W, Juntana S, Namwat N, et al. PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma[J]. Int J Cancer, 2011, 129(1): 34-44.
|
| [18] |
Soler A, Serra H, Pearce W, et al. Inhibition of the p110α isoform of PI3-kinase stimulates nonfunctional tumor angiogenesis[J]. J Exp Med, 2013, 210(10): 1937-1945.
|
| [19] |
McRee AJ, Sanoff HK, Carlson C, et al. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors[J]. Invest New Drugs, 2015, 33(6):1225-1231.
|
| [20] |
Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer[J]. Expert Opin Investig Drugs, 2011, 20(4): 507-518.
|
| [21] |
Dokduang H, Juntana S, Techasen A, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment[J]. Tumour Biol, 2013, 34(6): 3519-3528.
|
| [22] |
Ewald F, Grabinski N, Grottke A, et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma[J]. Int J Cancer, 2013, 133(9): 2065-2076.
|
| [23] |
Leelawat K, Udomchaiprasertkul W, Narong S, et al. Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells[J]. J Cancer Res Clin Oncol, 2010, 136(10): 1537-1544.
|